Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 9,154 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $163,398.90. Following the transaction, the chief executive officer now owns 642,602 shares in the company, valued at $11,470,445.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jeremy Bender also recently made the following trade(s):

• On Wednesday, May 1st, Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75.

Day One Biopharmaceuticals Stock Down 2.3 %

DAWN opened at $17.17 on Friday. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07. The firm has a 50-day simple moving average of $15.45 and a two-hundred day simple moving average of $14.02. The company has a market capitalization of $1.50 billion, a PE ratio of -7.21 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DAWN. Vanguard Group Inc. lifted its position in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 4.2% in the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock valued at $61,857,000 after acquiring an additional 169,463 shares during the last quarter. Braidwell LP grew its position in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its position in Day One Biopharmaceuticals by 9.0% during the third quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company’s stock valued at $23,742,000 after purchasing an additional 160,385 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DAWN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. Needham & Company LLC increased their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.